Patents Assigned to THE USA AS REPRESENTED BY THE SECRETARY, DEPT OF HEALTH AND HUMAN SERVICES
-
Patent number: 11944673Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.Type: GrantFiled: April 19, 2019Date of Patent: April 2, 2024Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, GlobeImmune, Inc.Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
-
Patent number: 11938175Abstract: Disclosed are yeast-based immunotherapeutic compositions comprising Brachyury antigens, and methods for the prevention and/or treatment of cancers characterized by the expression or overexpression of Brachyury.Type: GrantFiled: December 21, 2020Date of Patent: March 26, 2024Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, GlobeImmune, Inc.Inventors: Claudia Palena, Zhimin Guo, David Apelian, Jeffrey Schlom
-
Publication number: 20240084269Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.Type: ApplicationFiled: July 19, 2023Publication date: March 14, 2024Applicant: The Government of the USA as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
-
Patent number: 11827669Abstract: Antibodies and compositions of matter useful for the detection, diagnosis and treatment of Hepatitis B Virus infection in mammals, and to methods of using those compositions of matter for the same.Type: GrantFiled: July 19, 2018Date of Patent: November 28, 2023Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICESInventors: Paul T. Wingfield, Norman R. Watts, Alasdair C Steven
-
Publication number: 20230303501Abstract: Disclosed herein are embodiments of a compound that inhibits c-Abl tyrosine kinase (also referred to herein as “c-Abl”). The compound embodiments described herein are novel c-Abl inhibitors that can bind to c-Abl at an allosteric site and inhibit its activity in various pathways. The compound embodiments also are capable of crossing the blood brain barrier and therefore are useful in inhibiting c-Abl activity as it affects pathways and/or proteins in the brain. The compound embodiments described herein are effective therapeutic agents for treating diseases involving c-Abl, such as cancers, motor neuron diseases, and neurodegenerative diseases. Also disclosed herein are embodiments of methods for making and using the c-Abl inhibitory compound embodiments.Type: ApplicationFiled: March 30, 2023Publication date: September 28, 2023Applicants: The USA, as represented by the Secretary, Dept. of Health and Human Services, Pontificia Universidad Católica de ChileInventors: Juan J. Marugan, Marc Ferrer, Noel T. Southall, Andres E. Dulcey, Xin Hu, Christopher R. Dextras, Daniel C. Talley, Alejandra Alvarez, Silvana Zanlungo, Rommy M. Von Bernhardi
-
Publication number: 20230270833Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.Type: ApplicationFiled: October 18, 2022Publication date: August 31, 2023Applicant: The Government of the USA as represented by the Secretary of the Dept. of Health and Human ServicesInventors: Olen M. Kew, Cara Carthel Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
-
Patent number: 11732017Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.Type: GrantFiled: April 26, 2021Date of Patent: August 22, 2023Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-Yok Tsang
-
Patent number: 11718861Abstract: Described herein is a method of preventing or treating a disease in a mammalian subject, comprising administering to the subject who is in need thereof an effective dosage of a pharmaceutical composition comprising a virus like particle (VLP) comprising: an alphavirus replicon comprising a recombinant polynucleotide, wherein the polynucleotide comprises a sequence encoding both subunits of a human class II major histocompatibility antigen, a retroviral gag protein, and a fusogenic envelope protein, wherein the VLP does not contain an alphavirus structural protein gene.Type: GrantFiled: December 14, 2020Date of Patent: August 8, 2023Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Deb K. Chatterjee, Stanislaw J. Kaczmarczyk
-
Publication number: 20230242623Abstract: Compositions that selectively bind to coronaviruses, including but not limited to SARS-COV-2 and methods of use thereof are provided. The disclosed antibodies and antigen-binding fragments were developed against SARS-CoV-2. The antibodies bind to the spike protein of coronaviruses. The disclosed antibodies are useful for diagnosing, detecting, preventing, and treating coronavirus infections.Type: ApplicationFiled: July 8, 2021Publication date: August 3, 2023Applicants: GEORGIA TECH RESEARCH CORPORATION, THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICESInventors: M.G. FINN, Asheley CHAPMAN, Jason GOLDSTEIN, Liangjun ZHAO, Dennis Anthony BAGAROZZI, Jr., Asiya Seema CHIDA
-
Patent number: 11696941Abstract: A vaccine construct comprising an antigenic PCSK9 peptide and an immunogenic carrier, and methods of using the same that are effective to lower blood cholesterol levels in a mammal and treat dyslipidemias and related disease states in a mammal without the frequency of administration required by passive immunity strategies.Type: GrantFiled: January 22, 2021Date of Patent: July 11, 2023Assignees: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, UNM RAINFOREST INNOVATIONSInventors: Alan Remaley, John T. Schiller, Marcelo Amar, Bryce Chackerian
-
Patent number: 11655470Abstract: A single nucleotide polymorphism (SNP) that results in development of a Type VI collagen, alpha 1 chain-related disorder, and the use of the SNP to identify individuals at risk for developing COL6-related disorders (COL6-RD). Also provided are antisense oligomers for treating individuals at risk for developing COL6-RD, as well as methods for screening compounds for their potential as therapeutic agents.Type: GrantFiled: July 5, 2017Date of Patent: May 23, 2023Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Carsten G. Bonnemann, Veronique Bolduc, Francesco Muntoni, Steve Wilton, Daniel Macarthur, Monkol Lek, Beryl Cummings
-
Patent number: 11596675Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.Type: GrantFiled: November 18, 2020Date of Patent: March 7, 2023Assignees: GlobeImmune, Inc., The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
-
Patent number: 11590216Abstract: Disclosed are immunotherapeutic compositions and the concurrent use of combinations of such compositions for the improved induction of therapeutic immune responses and/or for the prevention, amelioration and/or treatment of disease, including, but not limited to, cancer and infectious disease.Type: GrantFiled: December 22, 2020Date of Patent: February 28, 2023Assignees: GlobelImmune, Inc., The USA, as represented by the Secretary, Dept, of Health and Human ServicesInventors: James Hodge, Jeffrey Schlom, Alex Franzusoff
-
Publication number: 20230017266Abstract: A method of treating an asthmatic subject is provided. The method includes determining serum level of serum amyloid A (SAA) in the subject; comparing the serum level with a pre-determined threshold; and administering to the subject a therapeutically effective amount of a COX-2 inhibitor if the serum level is greater than or equal to the threshold.Type: ApplicationFiled: December 3, 2020Publication date: January 19, 2023Applicant: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICESInventors: Stewart J. Levine, Xianglan Yao, Maryann Kaler, Alan T. Remaley, Amisha V. Barochia
-
Publication number: 20220251521Abstract: The invention is related to a dengue virus or chimeric dengue virus that contains a mutation in the 3? untranslated region (3?-UTR) comprising a ?30 mutation that removes the TL-2 homologous structure in each of the dengue virus serotypes 1, 2, 3, and 4, and nucleotides additional to the ?30 mutation deleted from the 3?-UTR that removes sequence in the 5? direction as far as the 5? boundary of the TL-3 homologous structure in each of the dengue serotypes 1, 2, 3, and 4, or a replacement of the 3?-UTR of a dengue virus of a first serotype with the 3?-UTR of a dengue virus of a second serotype, optionally containing the ?30 mutation and nucleotides additional to the ?30 mutation deleted from the 3?-UTR; and immunogenic compositions, methods of inducing an immune response, and methods of producing a dengue virus or chimeric dengue virus.Type: ApplicationFiled: April 19, 2022Publication date: August 11, 2022Applicant: The Government of the USA as represented by the Secretary, Dept. of Health and Human ServicesInventors: Stephen S. Whitehead, Joseph E. Blaney, Brian R. Murphy, Ching-Juh Lai
-
Patent number: 11324840Abstract: The present invention relates to a magnetic resonance structure with a cavity or a reserved space that provides contrast and the additional ability to frequency-shift the spectral signature of the NMR-susceptible nuclei such as water protons by a discrete and controllable characteristic frequency shift that is unique to each MRS design. The invention also relates to nearly uniform solid magnetic resonance T2* contrast agents that have a significantly higher magnetic moment compared to similarly-sized existing MRI contrast agents.Type: GrantFiled: March 4, 2019Date of Patent: May 10, 2022Assignees: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, THE USA, AS REPRESENTED BY THE SECRETARY OF COMMERCEInventors: Gary Zabow, Stephen Dodd, Alan Koretsky, John Moreland
-
Publication number: 20220010365Abstract: Methods for detecting presence of one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumooniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae, and Neisseria meningitidis nucleic acids in a sample, such as a biological sample obtained from a subject, or an environmental sample, are provided. This disclosure also provides probes, primers, and kits for detecting one or more of Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Toxoplasma gondii, Moraxella catarrhalis, Escherichia coli, Shigella, Staphylococcus aureus, Pneumocystis jirovecii, Chlamydia trachomatis, Ureaplasma urealyticum, Ureaplasma parvum, Ureaplasma spp., Bartonella spp., Streptococcus agalactiae, and Neisseria meningitidis in a sample.Type: ApplicationFiled: September 27, 2021Publication date: January 13, 2022Applicant: The Government of the USA as represented by the Secretary of the Dept. of Health and Human ServicesInventors: Bernard J. Wolff, Jonas M. Winchell, Maureen Diaz
-
Patent number: 11173278Abstract: Disclosed delivery catheters have a three-dimensional curvature that facilitates reaching the RAA from the inferior vena cava, positioning the distal end of the catheter generally parallel to the plane of the pericardial space at the puncture location within the RAA, orienting the puncturing device in a direction that avoids the right coronary artery, aorta, pulmonary artery, and other structures to prevent bystander injury to such structures, and provides sufficient rigidity to puncture through a wall of the RAA into the pericardial space.Type: GrantFiled: May 9, 2016Date of Patent: November 16, 2021Assignees: The USA, as represented by the Secretary, Dept. of Health and Human Services, Henry Ford Health SystemInventors: Robert J. Lederman, Toby Rogers, Nasser Rafiee, Adam B. Greenbaum, William W. O'Neill
-
Patent number: 11162892Abstract: A device (100) for measuring light transmission through a suspected counterfeit pharmaceutical tablet (102) includes a laser source (110) configured to emit a light transmission through the pharmaceutical tablet (102). A light detector (120) is included in the device (100) configured to receive the light transmission and measure an amount of light passed through the suspected counterfeit pharmaceutical tablet (102). The amount of light transmitted through the suspected counterfeit pharmaceutical tablet (102) is indicative of an authentic or counterfeit.Type: GrantFiled: January 27, 2017Date of Patent: November 2, 2021Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventor: Michael D. Green
-
Patent number: 11155588Abstract: The invention provides a human cytotoxic T lymphocyte (CTL) agonist epitope from the C-terminal subunit of mucin 1 (MUC1-C), which can be used as a peptide, polypeptide (protein), and/or in vaccine or other composition for the prevention or therapy of cancer. The invention further provides a nucleic acid encoding the peptide, protein, or polypeptide, a vector comprising the nucleic acid, a cell comprising the peptide, polypeptide, nucleic acid, or vector, and compositions thereof.Type: GrantFiled: December 16, 2019Date of Patent: October 26, 2021Assignee: The USA, as represented by the Secretary, Dept. of Health and Human ServicesInventors: Jeffrey Schlom, Kwong-Yok Tsang